Sanders Touts Progress on US Inhaler Product Price Investigation

An investigation on inhaler costs led by Sen. Bernie Sanders has pressured three pharmaceutical giants to cap out-of-pocket prices for their products within three months of the probe, the health committee chairman said Friday.

The moves from Boehringer Ingelheim, AstraZeneca PLC, and GlaxoSmithKline to cap the price at $35 a month for inhalers was touted by Sanders (I-Vt.) in a news conference discussing the progress of his investigation. The products are largely used for asthma and obstructive pulmonary disease.

“Less than three months after we launched our investigation, all three of these major corporations have made a commitment ...